Design considerations for dose-expansion cohorts in phase I trials

Journal of Clinical Oncology

Volumn 31, Issue 31, 2013, Pages 4014-4021

  Iasonos, Alexia ^a   O'Quigley, John ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; BEVACIZUMAB; BOSUTINIB; CARFILZOMIB; CONATUMUMAB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FIGITUMUMAB; FLUDARABINE; PAZOPANIB; RILOTUMUMAB; RITUXIMAB; SARACATINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT;

ACCURACY; ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ARTICLE; CANCER RECURRENCE; CLINICAL PROTOCOL; DOSE CALCULATION; DRUG DOSE; DRUG DOSE ESCALATION; DRUG DOSE EXPANSION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; GLIOBLASTOMA; HUMAN; LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; COHORT ANALYSIS; DOSE RESPONSE; METHODOLOGY; STANDARD; STANDARDS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; RESEARCH DESIGN;

EID: 84891600219     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.9949     Document Type: Article

References (32)

1. Annunziata CM, Kohn EC, LoRusso P, et al: Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs 31:77-84, 2013
2. Gordon MS, Sweeney CS, Mendelson DS, et al: Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 16:699-710, 2010
3. Herbst RS, Kurzrock R, Hong DS, et al: A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16:5883-5891, 2010
4. Srokowski TP, Liebmann J, Modiano MR, et al: Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Phase 1 study with a dose-expansion cohort. Cancer 117:5067-5073, 2011
5. Hurwitz HI, Dowlati A, Saini S, et al: Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220-4227, 2009
6. Daud AI, Krishnamurthi SS, Saleh MN, et al: Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 18:1092-1100, 2012
7. Reardon DA, Conrad CA, Cloughesy T, et al: Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol 69:1507-1518, 2012
8. Kaye S, Aamdal S, Jones R, et al: Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br J Cancer 106:1728-1734, 2012
9. Alsina M, Trudel S, Furman RR, et al: A phase I single-agent study of twice-weekly consecutiveday dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 18:4830-4840, 2012
10. Moroney J, Fu S, Moulder S, et al: Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: Tolerance and biological activity. Clin Cancer Res 18:5796-5805, 2012
11. Haluska P, Worden F, Olmos D, et al: Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65:765-73, 2010
12. Iasonos A, Wilton AS, Riedel ER, et al: A comprehensive comparison of the continual reassessment method to the standard 3+3 dose escalation scheme in phase I dose-finding studies. Clin Trials 5:465-477, 2008
13. O'Quigley J: Retrospective analysis of sequential dose-finding designs. Biometrics 61:749-756, 2005
14. Isambert N, Freyer G, Zanetta S, et al: Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 18:1743-1750, 2012
15. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46:33-48, 1990 (Pubitemid 20245604)
16. Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161, 1995
17. Ivanova A: A new dose finding design for bivariate outcomes. Biometrics 59:1001-1007, 2003
18. O'Quigley J, Hughes MD, Fenton T: Dose-finding design for HIV studies. Biometrics 57:1018-1029, 2001
19. O'Quigley J, Conaway M: Continual reassessment and related dose finding designs. Stat Sci 25:202-216, 2010
20. O'Quigley J, Conaway M: Extended model-based designs for more complex dose-finding studies. Stat Med 30:2062-2069, 2011
21. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
22. Iasonos A, Zohar S, O'Quigley J: Incorporating lower grade toxicity information into dose finding designs. Clin Trials 8:370-379, 2011
23. Lee SM, Cheng B, Cheung YK: Continual reassessment method with multiple toxicity constraints. Biostatistics 12:386-398, 2011
24. Van Meter EM, Garrett-Mayer E, Bandyopadhyay D: Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: An extension of the continual reassessment method. Clin Trials 9:303-313, 2012
25. Wages NA, Conaway MR, O'Quigley J: Continual reassessment method for partial ordering. Biometrics 67:1555-1563, 2011
26. Iasonos A, Ostrovnaya I: Estimating the dose-toxicity curve in completed phase I studies. Stat Med 30:2117-2129, 2011
27. O'Quigley J, Zohar S: Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer 94:609-613, 2006 (Pubitemid 43361888)
28. He W, Liu J, Binkowitz B, et al: A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials. Stat Med 25:2027-2042, 2006 (Pubitemid 43950277)
29. Stylianou M, Proschan M, Flournoy N: Estimating the probability of toxicity at the target dose following an up-and-down design. Stat Med 22:535-543, 2003 (Pubitemid 36204176)
30. Berry SM, Spinelli W, Littman GS, et al: A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clin Trials 7:121-135, 2010
31. Gönen M: A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in phase I trials. Contemp Clin Trials 26:131-140, 2005
32. Hamber P, Ratain MJ, Lessafre E, et al: Dose escalation models for combination phase I trials. Eur J Cancer 46:2870-2878, 2010